EDITORIAL SECTIONS
RESEARCH & DEVELOPMENT
Adopting the Power of AI to Drug Development Projects
A tremendous amount of documentation is created throughout the clinical trial lifecycle
CLINICAL TRIALS
Real-world Evidence
Hearing the diagnosis from the doctor that your child has spinal muscular atrophy SMA
MANUFACTURING
Just in Time Manufacturing Creating more sustainable supply chains
Drug development has transformed immeasurably over the past decade Even before the Covid pandemic and the conflict in Ukraine
Information Technology
Challenges and Advantages of Using Artificial Intelligence in Pharma
Many advanced largescale AI initiatives still need to be proved successful in Pharma
KNOWLEDGE BANK
Interviews
From Hallucinations to Evidence: LLMs clinicians can finally trust
Research Fellow, Institute of Health Informatics, University College London
Jinge Wu is a Research Fellow at the UCL Institute of Health Informatics specialising in multimodal large language models for clinical decision support and medical AI She has led research projects funded by UKRI MRC and Health Data Research UK working with largescale NHS electronic health record data to develop capable reliable and explainable AI for realworld clinical applications Her research ha...
Articles
Multi-Target Directed Ligands and Lipidomics Approach for Glioblastoma Drug Discovery
The traditional pharmaceutical approach of designing a diseasesymptomspecific drug has historically proven effective However this methodology often falls short due to the complex and often multifactorial etiology of diseases
Research Insights
Spectrophotometric determination of Ethionamide in Pharmaceuticals using Folin-Ciocalteu reagent and Iron (III)-Ferricyanide as Chromogenic Agents
Abstract Two simple and sensitive spectrophotometric methods are described for the determination of ethionamide ETM in pure drug and tablets The first method is based on the reduction of FolinCiocalteu FC reagent by ETM in sodium carbonate medium to form a blue coloured complex which was measured at nm Molybdenumtungsten blue method In the second me
Case Studies
Cyclodextrins as Active Pharmaceutical Ingredients for The Treatment Of GM1-Gangliosidosis: A Feasibility Case Study
Abstract GMgangliosidosis is a rare lysosomal storage disorder characterized clinically by a wide range of variable neurovisceral ophthalmological and dysmorphic features Without enough functional galactosidase GMgangliosides cannot be degraded in lysosomes and accumulate to toxic levels in many tissues and organs particularly in the brain In s
Techno Trends
CTP-543 Novel Therapy Introduced for the Treatment of Alopecia Areata
Concert Pharmaceuticals Inc introduces CTP Oral Janus kinase inhibitor for the treatment of moderatetosevere alopecia areata in adult patients
White Papers
Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches
In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS
TOP ARTICLES
Use of Steroids in COVID-19 patients
Anoop Kumar currently working as Assistant Professor in Department of Pharmacology and Clinical Research, Delhi Pharmaceutical Sciences & Research University (DPSRU), New Delhi, India. He has authored more than 70 research and review articles and 10 book chapters in International Journal of repute. His research interests are Drug repurposing, Meta-analysis, Risk and benefit analysis of drugs and Pharmacoeconomic studies.
Decoding Antisense Oligonucleotides: Mechanisms, Applications, and Future Directions
Dr. Arun Shastry is a Bengaluru-based scientist with a PhD in Immunogenetics. He is the Co-Founder, Managing Director, and Chief Scientific Officer (CSO) of Hanugen Therapeutics, a pioneering biopharmaceutical company focused on oligonucleotide-based therapies for rare genetic diseases, particularly Duchenne Muscular Dystrophy (DMD). With over two decades in drug discovery for rare disorders, Dr. Shastry drives affordable, accessible treatments through innovative personalized medicine approaches in India.
The Use of AI in Pharmacovigilance
Dr. Alejandra Guerchicoff is a Ph.D. in Molecular Genetics with postdoctoral training in Molecular Cardiology and Genetics of Cardiac Arrhythmias. She works as an Industry Advisor for the TCS ADD™ platform with the Life Sciences unit at TCS. Dr. Guerchicoff has over 20 years of experience in clinical research and post-marketing pharmacovigilance for medical devices, drugs, combination products, gene and cell therapy, and software for medical device products. She has authored many prestigious journal publications and books on diverse subjects and therapeutic areas. In her current role, Dr. Guerchicoff works on developing innovative technology solutions with AI and other modern technologies across various life sciences operations.
Innovative Approaches for Safer and More Effective Healthcare
Dani is a content strategist passionate about crafting compelling narratives. With a knack for blending creativity and data-driven insights, she specialises in developing content that engages and converts.
Unleashing the Power of Data, Collaboration, and Innovation in Drug Development
Pooja is a Healthcare & Life Sciences leader at Thoughtworks with over 15 years of experience in technology consulting. Specialising in AI-driven solutions and strategic initiatives that enhance drug discovery and patient care, she has a unique background in both bioinformatics and product management. Passionate about navigating ambiguity and solving customer problems, Pooja’s current focus is on leveraging emerging technologies to accelerate innovation in healthcare and life sciences.
press releasesRead more...
Telix and Ekalia to Collaborate on Astatine-211 Production in the U.S.
Telix and Ekalia a joint venture between IBA Ion Beam Applications SA EURONEXT and Framatome today announced a collaboration to advance scalable United States US production of astatine At an alphaemitting radioisotope being investigated for targeted alpha therapy
HistoIndex and A*STAR Partner To Advance Early – Stage Development Of Pipeline Therapies For Fibrotic Diseases
HistoIndex a pioneer in AIdriven digital pathology for fibrotic diseases and the Agency for Science Technology and Research ASTAR Singapores lead public sector RD agency have signed a Memorandum of Understanding MoU to collaborate on the preclinical evaluation
Cotecna Group Acquires Energon Labs
Cotecna a leading provider of Testing Inspection and Certification TIC services today announced the acquisition of Energon Labs a cGMPcompliant USFDAinspected ISO and ISO certified analytical testing laboratory based in Hyderabad India
Waters Launches AI Link, Advancing AI-Enabled LC-MS Workflows from Research to Release
Waters Corporation announced that it has launched Waters AI Link a software capability that brings Anthropics Model Context Protocol MCP to its informatics platform and has joined Anthropics Model Hardware Standard MHS research program
Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 1
Takeda announced that ORZEYFUL oveporexton is now available in Japan and China for the treatment of narcolepsy type NT providing first access to clinicians to prescribe treatment with the new class of medicine ORZEYFUL is a firstinclass orexin receptor OXR agonist in tablet form designed to treat...
Merck Inaugurates State-of-the-Art ADVANCE Bioanalytical Facility on West Point, Pennsylvania, Campus
Merck known as MSD outside of the United States and Canada today inaugurated its stateoftheart ADVANCE research facility on its West Point Pennsylvania campus signaling a new chapter in global scientific discovery Pennsylvania Gov Josh Shapiro joined Merck executive leadership federal and state gove...
EventsRead more...
26 - 28
Oct 2026ACHEMA Middle East 2026
RICEC, Riyadh, KSA, Saudi Arab...
26 - 28
Oct 2026World Orphan Drug Congress
RAI, Amsterdam, Netherlands
27 - 28
Oct 2026PM& AC 2026
Novotel Hyderabad Convention C...
28 - 30
Oct 2026BIOPLUS-INTERPHEX KOREA 2026
COEX, Seoul
02 - 04
Nov 2026Pharma Forum EMEA 2026
Dom Pedro Lisboa Hotel, Lisbon...
02 - 04
Nov 2026Cancer R&D 2026
Houston, TX, USA
03 - 05
Nov 202610th Dermatology Drug Development
Boston, Massachusetts at The C...
03 - 04
Nov 2026PDA Aseptic Processing of Biopharma Conference
Sheraton Grand Incheon Hotel,...
LATEST NEWSRead more...
UCB Receives Approval for ZILBRYSQ Autoinjector for Adults with Generalised Myasthenia Gravis
UCB has received approval from the US Food and Drug Administration FDA for a new autoinjector option for ZILBRYSQ zilucoplan a treatment for adults with generalised myasthenia gravis gMG who test positive for antiacetylcholine receptor AChR antibodies
Nxera Pharma Partners with Synmosa to Commercialise QUVIVIQ
Nxera Pharma has entered into an exclusive licensing supply and commercialisation agreement with Synmosa Biopharma to expand access to QUVIVIQ daridorexant a medicine used to treat insomnia across eight AsiaPacific markets QUVIVIQ was discovered and developed by Idorsia Pharmaceuticals
Vir Biotechnology Enters into Collaboration with Gilead Sciences to Develop T-cell Engagers for Solid Tumours
Vir Biotechnology has entered into a collaboration and licensing agreement with Gilead Sciences to discover and develop three novel Tcell engager TCE candidates for the treatment of solid tumours Tcell engagers are designed to direct T cells a type of immune cell towards cancer cells and help destro...
Zealand Pharma Enters into Collaboration with Generate Biomedicines on AI-Designed Protein Therapies for Metabolic Diseases
Zealand Pharma and Generate Biomedicines have entered into a multitarget collaboration and licensing agreement to develop proteinbased treatments for obesity and other metabolic diseases using artificial intelligence AI The collaboration will combine Zealand Pharmas expertise in metabolic diseases w...
Enodia Therapeutics Enters into Collaboration with Pfizer to Develop Small-Molecule Sec61 Inhibitors
Enodia Therapeutics has entered into a research collaboration and licensing agreement with Pfizer to discover and develop smallmolecule inhibitors targeting Sec a protein complex involved in the movement of newly formed proteins across cell membranes
InnoCare Announces Approval of Clinical Trial of Bispecific Antibody ICP-B161 Targeting TL1A and IL-23p19 in China
InnoCare Pharma a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases announced today that the Center for Drug Evaluation CDE of Chinas National Medical Products Administration NMPA has approved its Investigational New Drug IND application for ICPB a bispeci...